Eli Lilly and Company (LLY)vsOmniAb Inc. (OABI)
LLY
Eli Lilly and Company
$851.21
+9.80%
HEALTHCARE · Cap: $760.43B
OABI
OmniAb Inc.
$1.36
-2.86%
HEALTHCARE · Cap: $208.49M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 349086% more annual revenue ($65.18B vs $18.67M). LLY leads profitability with a 31.7% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
OABI
Avoid27
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 28.7x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : OABI
The strongest argument for OABI centers on Price/Book, Debt/Equity, Altman Z-Score.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : OABI
The primary concerns for OABI are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
LLY profiles as a growth stock while OABI is a value play — different risk/reward profiles.
OABI carries more volatility with a beta of 0.87 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 27/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →OmniAb Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
OmniAb Inc. is a pioneering biotechnology firm focused on the creation of fully human therapeutic antibodies through its cutting-edge OmniAb platform. This unique technology facilitates the rapid discovery and refinement of high-efficacy therapeutics to tackle a diverse range of diseases. By fostering strategic partnerships and collaborations, OmniAb strives to expedite drug development and broaden access to innovative therapies. With an experienced leadership team and a strong product pipeline, the company is well-positioned to seize expanding opportunities within the biopharmaceutical landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?